Performance of Xpert HIV-1 viral load test in Senegal: a country of high circulation of CRF02_AG

Pan Afr Med J. 2022 Jun 20:42:136. doi: 10.11604/pamj.2022.42.136.32041. eCollection 2022.

Abstract

Introduction: the introduction of the point-of-care in HIV-1 viral load quantification appears to be a complementary strategy to the existing conventional system of the acceleration plan for the achievement of the three 90s in Senegal. The objective of this study was to evaluate the performance of the Xpert® HIV-1 viral load in the context of circulation of non-B, non-C subtypes.

Methods: two hundred samples, were tested on Xpert® HIV-1 Viral Load using 1 ml of plasma in comparison to 600 μl on Abbott Real-time HIV-1 assay. The difference between viral load values was considered significant for Dlog <0.5 log copies/ml.

Results: a good correlation (r=0.985) was noted and confirmed using passing-bablok regression (slope 1.048; 95% CI: 1.036 to 1.069) for 188 samples with samples. A mean difference of 0.0075 log10 copies/ml for a 95% confidence interval (CI) of 0.002 log10 copies/ml to 0.013 log10 copies/ml was obtained. Sensitivity and specificity were respectively 93.6% and 93.5% at the threshold of 1.6 log10 copies/ml and 100% and 99% at the threshold of 3.0 log10 copies/ml.

Conclusion: these results show that Xpert® HIV-1 Viral Load has excellent performance. In Senegal, and can be used for HIV viral load monitoring.

Keywords: CRF02_AG; HIV-1; Senegal; plasma; point of care system; viral load.

MeSH terms

  • HIV Infections* / diagnosis
  • HIV-1* / genetics
  • Humans
  • RNA, Viral
  • Senegal
  • Viral Load

Substances

  • RNA, Viral